Abstract Background Gastrointestinal stromal tumours (GISTs) are rare, yet the most
common mesenchymal tumour within the digestive tract. Lack of diagnostic criteria and no …

Background The risk of recurrence of gastrointestinal stromal tumour (GIST) after surgery
needs to be estimated when considering adjuvant systemic therapy. We assessed …

Sarcomas are a heterogeneous group of malignant neoplasms arising from mesenchymal
cells which encompass dozens of histological types and can occur in virtually any anatomic …

Context Adjuvant imatinib administered for 12 months after surgery has improved recurrence-
free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared …

Accurate risk stratification of gastrointestinal stromal tumors (GISTs) has become
increasingly important owing to emerging adjuvant systemic treatments. All GISTs have …

Background Adjuvant imatinib mesylate prolongs recurrence-free survival (RFS) after
resection of localised primary gastrointestinal stromal tumours (GIST). We aimed to develop …

Gastrointestinal stromal tumors are rare malignancies involving the intestinal tract. They are
now easily recognized using standard immunohistochemistry. Management in the past was …

Purpose Mutated KIT and platelet-derived growth factor alpha gene (PDGFRA) drive GI
stromal tumor (GIST) oncogenesis, but the clinical significance of their single mutations is …

Gastrointestinal stromal tumor has received a lot of attention over the last 10 years due to its
unique biologic behavior, clinicopathological features, molecular mechanisms, and …

Gastrointestinal stromal tumors (GISTs) are rare life-threatening forms of cancer that may
arise anywhere in the GI tract. Herein, we aimed to review the literature to describe the …